Atrioventricular Node Ablation in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure
- Conditions
- Heart Failure
- Interventions
- Device: Implantation of CRT deviceDevice: Implantation of conventional VVI(R) pacemaker
- Registration Number
- NCT01512381
- Lead Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
- Brief Summary
The purpose of this study is to determine whether cardiac resynchronization therapy (CRT) is superior to interventricular right ventricle (RV) septal pacing in respect of reverse remodeling (LV ESD) and morbidity in patients with less preserved (less than 45%) ejection fraction (EF), persistent/permanent atrial fibrillation (AF) who successfully received atrioventricular (AV) junction ablation ablation (100% pacemaker dependency)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 11
- Age of 18-75 years
- CHF II-III NYHA
- Persistent/permanent AF requiring AV node ablation
- LVEF < 45%
- Signed informed consent
- Able to complete all testing required by the clinical protocol
- Myocardial infarction or stroke less than 3 months prior to randomization
- Patients who require revascularization, radiofrequency ablation of pulmonary veins and substrate of AF
- The congenital and acquired heart diseases, LV aneurysm, which requires a surgical correction
- Active inflammatory and autoimmune diseases of a myocardium
- The thyrotoxicosis
- The diseases that limit life expectancy (cancer, tuberculosis, etc.)
- Contraindications to anticoagulants administration at CHADS2> 2
- Uncompliant patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CRT Implantation of CRT device - pacemaker Implantation of conventional VVI(R) pacemaker -
- Primary Outcome Measures
Name Time Method Left Ventricle End-Systolic Volume (LV ESV) 12 months
- Secondary Outcome Measures
Name Time Method Echocardiographic indexes of LV remodeling 12 months Changes in NYHA functional class measured by peak V O2 oxygen consumption and distance of 6-minute walk test 12 months Changes in Quality of Life (measured by Minnesota Living with Heart Failure Questionnaire) 12 months Rate of cardiovascular events (hospitalization for worsening heart failure) 12 month
Trial Locations
- Locations (1)
Almazov Federal Heart, Blood and Endocrinology Centre
🇷🇺Saint-Petersburg, Russian Federation